Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey
Tóm tắt
Từ khóa
Tài liệu tham khảo
Vale CL, Fisher DJ, White IR et al (2018) What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol 29(5):1249–1257
Gravis G, Gravis G, Boher JM et al (2018) Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 73(6):847–855
Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137
Arcangeli S, Zilli T, De Bari B, Alongi F (2016) “Hit the primary”: a paradigm shift in the treatment of metastatic prostate cancer? Crit Rev Oncol Hematol 97:231–237
Koo KC, Dasgupta P (2018) Treatment of oligometastatic hormone-sensitive prostate cancer: a comprehensive review. Yonsei Med J 59(5):567–579
Gillessen S, Attard G, Beer TM et al (2018) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73(2):178–211
Francini E, Gray KP, Xie W et al (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78(12):889–895
Pillay B, Wootten AC, Crowe H et al (2016) The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev 42:56–72
Rao K, Manya K, Azad A et al (2014) Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre—impact on clinical decision-making and implications for patient inclusion. BJU Int 114(Suppl 1):50–54
Kurpad R, Kim W, Rathmell WK et al (2011) A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Urol Oncol 29(4):378–382
National Comprehensive Cancer Network clinical practice guidelines in oncology, version 3.2018. National Comprehensive Cancer Network 2011, Jenkintown. http://www.nccn.org
Pasoglou V, Larbi A, Collette L et al (2014) One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified “all-in-one” imaging approach? Prostate 74(5):469–477
Larbi A, Dallaudière B, Pasoglou V et al (2016) Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: therapeutic perspectives on targeted management of oligometastatic disease. Prostate 76(11):1024–1033
Joice GA, Rowe SP, Pienta KJ, Gorin MA (2017) Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. Curr Opin Urol 27(6):533–541
Ost P, Decaestecker K, Lambert B et al (2014) Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74:297–305
Saluja R, Cheung P, Zukotynski K, Emmenegger U (2016) Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: from chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases. Urol Oncol 34(5):225–232
De Bari B, Arcangeli S, Ciardo D, On the behalf of the Italian Association of Radiation Oncology (AIRO) et al (2016) Extreme hypofractionation for early prostate cancer: biology meets technology. Cancer Treat Rev 50:48–60
Nair R, Lamb BW, Geurts N et al (2017) The role of local therapy for oligometastatic prostate cancer: should we expect a cure? Urol Clin North Am 44(4):623–633
Cho Y, Chang JS, Rha KH et al (2016) Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis? PLoS ONE 11(1):e0147191
Riva G, Marvaso G, Augugliaro M et al (2017) Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome. Ecancermedicalscience 30(11):786
Koo KC, Dasgupta P (2018) Treatment of oligometastatic hormone-sensitive prostate cancer: a comprehensive review. Yonsei Med J 59(5):567–579
Henderson DR, Tree AC, van As NJ (2015) Stereotactic body radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol) 27(5):270–279
Miralbell R, Roberts SA, Zubizarreta E, Hendry JH (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 82(1):e17–e24